Forewarned is forearmed: erythropoietin use in CKD patients with cancer.
Nayak-Rao and McCormick raise important concerns about erythropoietin use in patients with chronic kidney disease and cancer, and appropriately build a case for caution in this setting (J Nephrol. 2013, in press). Their comprehensive and insightful review highlights both the clinical and the basic science considerations that form the basis for this warning.